Table 1 Clinical and imaging characteristics, and immunostaining findings.
Total, n = 29 (%) | ACP, n = 18 (%) | PCP, n = 11 (%) | p value | |
|---|---|---|---|---|
Age | ||||
0–19 | 4 (13.8) | 4 (22.2) | 0 (0.0) | |
20–39 | 6 (20.7) | 4 (22.2) | 2 (18.2) | |
40–59 | 12 (41.4) | 8 (44.4) | 4 (36.4) | |
60–79 | 7 (24.1) | 2 (11.1) | 5 (45.5) | |
Sex | ||||
M | 15 (51.7) | 7 (38.9) | 8 (72.7) | 0.128 |
F | 14 (48.3) | 11 (61.1) | 3 (27.3) | |
Size | ||||
Median | 34.8 | 37.5 | 28.4 | 0.105 |
IQR | 23.6–41 | 27.1–44.7 | 22.9–37.3 | |
Cyst formation | ||||
+ | 17 (58.6) | 13 (72.2) | 4 (36.4) | 0.13 |
− | 12 (41.4) | 5 (27.8) | 7 (63.6) | |
Calcification | ||||
+ | 17 (58.6) | 17 (94.4) | 0 (0.0) | < 0.01 |
− | 12 (41.4) | 1 (5.6) | 11 (100) | |
Approach | ||||
Nasal | 19 (65.5) | 12 (66.7) | 7 (63.6) | 1 |
Craniotomy | 10 (34.5) | 6 (33.3) | 4 (36.4) | |
Past surgery | ||||
Initial surgery | 26 (89.7) | 16 (88.9) | 10 (90.9) | 1 |
Recurrent tumor | 3 (10.3) | 2 (11.1) | 1 (9.1) | |
Removal extent | ||||
Median | 95 | 95 | 95 | 0.98 |
IQR | 90–100 | 90–100 | 92.5–100 | |
Immunostaining | ||||
GLUT-1 | ||||
Positive | 13 (44.8) | 4 (22.2) | 9 (81.8) | 0.003 |
Negative | 16 (55.2) | 14 (77.8) | 2 (18.2) | |
HK-II | ||||
Positive | 10 (34.5) | 2 (11.1) | 8 (72.7) | 0.001 |
Negative | 19 (65.5) | 16 (88.9) | 3 (27.3) | |
BRAF V600E | ||||
Positive | 10 (34.5) | 0 (0.0) | 10 (90.9) | < 0.001 |
Negative | 19 (65.5) | 18 (100) | 1 (9.1) | |
Nuclear expression of beta-catenin | ||||
Observed | 18 (62.1) | 18 (100) | 0 (0.0) | < 0.001 |
Not observed | 11 (37.9) | 0 (0.0) | 11 (100) | |
